Canakinumab

Generic Name
Canakinumab
Brand Names
Ilaris
Drug Type
Biotech
Chemical Formula
-
CAS Number
914613-48-2
Unique Ingredient Identifier
37CQ2C7X93
Background

Canakinumab is a recombinant, human anti-human-IL-1ฮฒ monoclonal antibody that belongs to the IgG1/ฮบ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy chains of canakinumab contain ...

Indication

Canakinumab is indicated for the treatment of periodic fever syndromes in specific patient populations. In patients โ‰ฅ4 years of age, canakinumab is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS). In adult and pediatric patients, canakinum...

Associated Conditions
Adult Onset Still's Disease, Cryopyrin-associated Periodic Syndromes (CAPS), Familial Cold Autoinflammatory Syndrome (FCAS), Familial Mediterranean Fever (FMF ), Gout Flares, Mevalonate Kinase Deficiency, Muckle-Wells Syndrome (MWS), Systemic Juvenile Idiopathic Arthritis (SJIA), Tumour necrosis factor receptor-associated periodic syndrome
Associated Therapies
-

Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients

First Posted Date
2009-05-12
Last Posted Date
2012-02-20
Lead Sponsor
Novartis
Target Recruit Count
556
Registration Number
NCT00900146
Locations
๐Ÿ‡ฆ๐Ÿ‡ท

Centro de Investigaciones Clinicas del Litoral, Santa Fe, Argentina

๐Ÿ‡ต๐Ÿ‡ช

Clinica Chiclayo, Chiclayo, Peru

๐Ÿ‡ฎ๐Ÿ‡ณ

King George Hospital, Visakhapatnam, India

and more 85 locations

An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naรฏve Patients With Active SJIA With and Without Fever.

Phase 3
Completed
Conditions
Interventions
First Posted Date
2009-04-30
Last Posted Date
2019-03-26
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
270
Registration Number
NCT00891046
Locations
๐Ÿ‡ฌ๐Ÿ‡ง

Novartis Investigative Site, Oxford, United Kingdom

Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)

First Posted Date
2009-04-29
Last Posted Date
2012-10-16
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
177
Registration Number
NCT00889863
Locations
๐Ÿ‡บ๐Ÿ‡ธ

University of Louisville, Louisville, Kentucky, United States

๐Ÿ‡บ๐Ÿ‡ธ

Tufts Medical Center, Boston, Massachusetts, United States

๐Ÿ‡น๐Ÿ‡ท

Novartis Investigative Site, Izmir, Turkey

and more 11 locations

Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)

First Posted Date
2009-04-23
Last Posted Date
2017-03-29
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
84
Registration Number
NCT00886769
Locations
๐Ÿ‡บ๐Ÿ‡ธ

St. Barnabas Ambulatory Care Center, Livingston, New Jersey, United States

๐Ÿ‡บ๐Ÿ‡ธ

University of Chicago Medical Center, Chicago, Illinois, United States

๐Ÿ‡บ๐Ÿ‡ธ

Arkansas Children's Hospital Research Inst, Little Rock, Arkansas, United States

and more 14 locations

A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)

First Posted Date
2009-01-09
Last Posted Date
2018-07-17
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
432
Registration Number
NCT00819585
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Talbert Medical Group, Huntington Beach, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Health Awareness, Jupiter, Florida, United States

๐Ÿ‡บ๐Ÿ‡ธ

East-West Medical Research institute, Honolulu, Hawaii, United States

and more 28 locations

Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients

Phase 2
Completed
Conditions
Interventions
First Posted Date
2008-11-26
Last Posted Date
2012-04-10
Lead Sponsor
Novartis
Target Recruit Count
200
Registration Number
NCT00798369
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Montana Medical Research, Missoula, Montana, United States

๐Ÿ‡บ๐Ÿ‡ธ

Northwest Clinical Trials, Boise, Idaho, United States

๐Ÿ‡ฌ๐Ÿ‡ง

Novartis Investigative Site, Wellingborough, United Kingdom

and more 26 locations

Canakinumab to Treat Neonatal-Onset Multisystem Inflammatory Disease

Phase 3
Terminated
Conditions
Interventions
First Posted Date
2008-10-10
Last Posted Date
2021-06-10
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
7
Registration Number
NCT00770601
Locations
๐Ÿ‡บ๐Ÿ‡ธ

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), 9, Bethesda, Maryland, United States

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Rheumatoid Arthritis With Ongoing Treatment With Methotrexate

Phase 1
Completed
Conditions
Interventions
First Posted Date
2008-02-21
Last Posted Date
2008-02-21
Lead Sponsor
Novartis
Target Recruit Count
53
Registration Number
NCT00619905
Locations
๐Ÿ‡จ๐Ÿ‡ญ

Novartis Investigator Site, Geneva, Switzerland

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Type 2 Diabetes

First Posted Date
2008-01-31
Last Posted Date
2012-02-13
Lead Sponsor
Novartis
Target Recruit Count
231
Registration Number
NCT00605475
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Allied Research International - Cetero Research Miami, Miami, Florida, United States

๐Ÿ‡บ๐Ÿ‡ธ

Elite Research Institute Miami, Miami, Florida, United States

๐Ÿ‡ท๐Ÿ‡บ

Novartis Investigative Site, St. Petersberg, Russian Federation

and more 5 locations

Safety and Efficacy of Multiple Doses of Canakinumab (ACZ885) in Chronic Obstructive Pulmonary Disease (COPD) Patients

First Posted Date
2007-12-28
Last Posted Date
2011-06-30
Lead Sponsor
Novartis
Target Recruit Count
147
Registration Number
NCT00581945
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Novartis Investigator Site, Richmond, Virginia, United States

ยฉ Copyright 2024. All Rights Reserved by MedPath